Insulin Dose Articles & Analysis: This-Week
2 news found
The data support CFTX-2034 as a potential first-in-class PBH therapy and advance the program toward IND-enabling studies.CFTX-2034 is a long-acting, highly selective agonistic antibody designed to target somatostatin receptor subtype 5 (SSTR5), a key regulator of insulin and incretin secretion. The aim is to restore glycemic control and reduce hypoglycemic episodes following ...
The data support CFTX-2034 as a potential first-in-class PBH therapy and advance the program toward IND-enabling studies.CFTX-2034 is a long-acting, highly selective agonistic antibody designed to target somatostatin receptor subtype 5 (SSTR5), a key regulator of insulin and incretin secretion. The aim is to restore glycemic control and reduce hypoglycemic episodes following ...